Skip to main content
Top
Published in: Journal of Gastroenterology 8/2017

01-08-2017 | Original Article—Alimentary Tract

Indigo Naturalis ameliorates murine dextran sodium sulfate-induced colitis via aryl hydrocarbon receptor activation

Authors: Shoichiro Kawai, Hideki Iijima, Shinichiro Shinzaki, Satoshi Hiyama, Toshio Yamaguchi, Manabu Araki, Shuko Iwatani, Eri Shiraishi, Akira Mukai, Takahiro Inoue, Yoshito Hayashi, Masahiko Tsujii, Daisuke Motooka, Shota Nakamura, Tetsuya Iida, Tetsuo Takehara

Published in: Journal of Gastroenterology | Issue 8/2017

Login to get access

Abstract

Background

Indigo Naturalis (IN) is used as a traditional herbal medicine for ulcerative colitis (UC). However, the mechanisms of action of IN have not been clarified. We aimed to evaluate the efficacy of IN for ameliorating colonic inflammation. We further investigated the mechanisms of action of IN.

Methods

Colitis severity was assessed in dextran sodium sulfate-induced colitis and trinitrobenzene sulfonic acid-induced colitis models with or without the oral administration of IN or indigo, which is a known major component of IN. Colonic lamina propria (LP) mononuclear cells isolated from IN-treated mice were analyzed with quantitative reverse transcription polymerase chain reaction (qRT-PCR) and flow cytometry. LP and splenic mononuclear cells cultured in vitro with IN or indigo were also analyzed. The role of the candidate receptor for indigo, the aryl hydrocarbon receptor (AhR), was analyzed using Ahr-deficient mice.

Results

Colitis severity was significantly ameliorated in the IN and indigo treatment groups compared with the control group. The mRNA expression levels of interleukin (Il)-10 and Il-22 in the LP lymphocytes were increased by IN treatment. The treatment of splenocytes with IN or indigo increased the expression of anti-inflammatory cytokines and resulted in the expansion of IL-10-producing CD4+ T cells and IL-22-producing CD3RORγt+ cells, but not CD4+Foxp3+ regulatory T cells. The amelioration of colitis by IN or indigo was abrogated in Ahr-deficient mice, in association with diminished regulatory cytokine production.

Conclusions

IN and indigo ameliorated murine colitis through AhR signaling activation, suggesting that AhR could be a promising therapeutic target for UC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ochsenkühn T, D’Haens G. Current misunderstandings in the management of ulcerative colitis. Gut. 2011;60:1294–9.CrossRefPubMed Ochsenkühn T, D’Haens G. Current misunderstandings in the management of ulcerative colitis. Gut. 2011;60:1294–9.CrossRefPubMed
2.
go back to reference Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909–15.CrossRefPubMed Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909–15.CrossRefPubMed
3.
go back to reference Ng SC, Lam YT, Tsoi KK, et al. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:854–63.CrossRefPubMed Ng SC, Lam YT, Tsoi KK, et al. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:854–63.CrossRefPubMed
4.
go back to reference Triantafyllidi A, Xanthos T, Papalois A, et al. Herbal and plant therapy in patients with inflammatory bowel disease. Ann Gastroenterol. 2015;28:210–20.PubMedPubMedCentral Triantafyllidi A, Xanthos T, Papalois A, et al. Herbal and plant therapy in patients with inflammatory bowel disease. Ann Gastroenterol. 2015;28:210–20.PubMedPubMedCentral
5.
go back to reference Plitzko I, Mohn T, Sedlacek N, et al. Composition of Indigo naturalis. Planta Med. 2009;75:860–3.CrossRefPubMed Plitzko I, Mohn T, Sedlacek N, et al. Composition of Indigo naturalis. Planta Med. 2009;75:860–3.CrossRefPubMed
6.
go back to reference Deng S, May BH, Zhang AL, et al. Plant extracts for the topical management of psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169:769–82.CrossRefPubMed Deng S, May BH, Zhang AL, et al. Plant extracts for the topical management of psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169:769–82.CrossRefPubMed
7.
go back to reference Suzuki H, Kaneko T, Mizokami Y, et al. Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis. World J Gastroenterol. 2013;19:2718–22.CrossRefPubMedPubMedCentral Suzuki H, Kaneko T, Mizokami Y, et al. Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis. World J Gastroenterol. 2013;19:2718–22.CrossRefPubMedPubMedCentral
8.
go back to reference Fukunaga K, Ohda Y, Hida N, et al. Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. J Gastroenterol Hepatol. 2012;27:1808–15.CrossRefPubMed Fukunaga K, Ohda Y, Hida N, et al. Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. J Gastroenterol Hepatol. 2012;27:1808–15.CrossRefPubMed
9.
go back to reference Zhang F, Li Y, Xu F, et al. Comparison of Xilei-san, a Chinese herbal medicine, and dexamethasone in mild/moderate ulcerative proctitis: a double-blind randomized clinical trial. J Altern Complement Med. 2013;19:838–42.CrossRefPubMed Zhang F, Li Y, Xu F, et al. Comparison of Xilei-san, a Chinese herbal medicine, and dexamethasone in mild/moderate ulcerative proctitis: a double-blind randomized clinical trial. J Altern Complement Med. 2013;19:838–42.CrossRefPubMed
10.
go back to reference Sugimoto S, Naganuma M, Kiyohara H, et al. Clinical efficacy and safety of oral Qing-Dai in patients with ulcerative colitis: a single-center open-label prospective study. Digestion. 2016;93:193–201.CrossRefPubMed Sugimoto S, Naganuma M, Kiyohara H, et al. Clinical efficacy and safety of oral Qing-Dai in patients with ulcerative colitis: a single-center open-label prospective study. Digestion. 2016;93:193–201.CrossRefPubMed
11.
go back to reference Sugimoto S, Naganuma M, Kanai T. Indole compounds may be promising medicines for ulcerative colitis. J Gastroenterol. 2016;51:853–61.CrossRefPubMed Sugimoto S, Naganuma M, Kanai T. Indole compounds may be promising medicines for ulcerative colitis. J Gastroenterol. 2016;51:853–61.CrossRefPubMed
12.
go back to reference Stockinger B, Di Meglio P, Gialitakis M, et al. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol. 2014;32:403–32.CrossRefPubMed Stockinger B, Di Meglio P, Gialitakis M, et al. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol. 2014;32:403–32.CrossRefPubMed
13.
go back to reference Sugihara K, Okayama T, Kitamura S, et al. Comparative study of aryl hydrocarbon receptor ligand activities of six chemicals in vitro and in vivo. Arch Toxicol. 2008;82:5–11.CrossRefPubMed Sugihara K, Okayama T, Kitamura S, et al. Comparative study of aryl hydrocarbon receptor ligand activities of six chemicals in vitro and in vivo. Arch Toxicol. 2008;82:5–11.CrossRefPubMed
14.
go back to reference Adachi J, Mori Y, Matsui S, et al. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J Biol Chem. 2001;276:31475–8.CrossRefPubMed Adachi J, Mori Y, Matsui S, et al. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J Biol Chem. 2001;276:31475–8.CrossRefPubMed
15.
go back to reference Monteleone I, Rizzo A, Sarra M, et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology. 2011;141:237–48, 248.e1. Monteleone I, Rizzo A, Sarra M, et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology. 2011;141:237–48, 248.e1.
16.
go back to reference Nguyen NT, Nakahama T, Le DH, et al. Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol. 2014;5:551.CrossRefPubMedPubMedCentral Nguyen NT, Nakahama T, Le DH, et al. Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol. 2014;5:551.CrossRefPubMedPubMedCentral
17.
go back to reference Shiraishi E, Iijima H, Shinzaki S, et al. Vitamin K deficiency leads to exacerbation of murine dextran sulfate sodium-induced colitis. J Gastroenterol. 2016;51:346–56.CrossRefPubMed Shiraishi E, Iijima H, Shinzaki S, et al. Vitamin K deficiency leads to exacerbation of murine dextran sulfate sodium-induced colitis. J Gastroenterol. 2016;51:346–56.CrossRefPubMed
18.
go back to reference Li Y, Innocentin S, Withers DR, et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell. 2011;147:629–40.CrossRefPubMed Li Y, Innocentin S, Withers DR, et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell. 2011;147:629–40.CrossRefPubMed
19.
go back to reference Shinzaki S, Ishii M, Fujii H, et al. N-acetylglucosaminyltransferase V exacerbates murine colitis with macrophage dysfunction and enhances colitic tumorigenesis. J Gastroenterol. 2016;51:357–69. Shinzaki S, Ishii M, Fujii H, et al. N-acetylglucosaminyltransferase V exacerbates murine colitis with macrophage dysfunction and enhances colitic tumorigenesis. J Gastroenterol. 2016;51:357–69.
20.
go back to reference Furumatsu K, Nishiumi S, Kawano Y, et al. A role of the aryl hydrocarbon receptor in attenuation of colitis. Dig Dis Sci. 2011;56:2532–44.CrossRefPubMed Furumatsu K, Nishiumi S, Kawano Y, et al. A role of the aryl hydrocarbon receptor in attenuation of colitis. Dig Dis Sci. 2011;56:2532–44.CrossRefPubMed
21.
go back to reference Aicher WK, Fujihashi K, Yamamoto M, et al. Effects of the lpr/lpr mutation on T and B cell populations in the lamina propria of the small intestine, a mucosal effector site. Int Immunol. 1992;4:959–68.CrossRefPubMed Aicher WK, Fujihashi K, Yamamoto M, et al. Effects of the lpr/lpr mutation on T and B cell populations in the lamina propria of the small intestine, a mucosal effector site. Int Immunol. 1992;4:959–68.CrossRefPubMed
22.
23.
go back to reference Dohi T, Ejima C, Kato R, et al. Therapeutic potential of follistatin for colonic inflammation in mice. Gastroenterology. 2005;128:411–23.CrossRefPubMed Dohi T, Ejima C, Kato R, et al. Therapeutic potential of follistatin for colonic inflammation in mice. Gastroenterology. 2005;128:411–23.CrossRefPubMed
24.
25.
go back to reference Gandhi R, Kumar D, Burns EJ, et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol. 2010;11:846–53.CrossRefPubMedPubMedCentral Gandhi R, Kumar D, Burns EJ, et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol. 2010;11:846–53.CrossRefPubMedPubMedCentral
26.
go back to reference Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev. 2013;252:116–32.CrossRefPubMed Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev. 2013;252:116–32.CrossRefPubMed
27.
go back to reference Spits H, Artis D, Colonna M, et al. Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13:145–9.CrossRefPubMed Spits H, Artis D, Colonna M, et al. Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13:145–9.CrossRefPubMed
28.
go back to reference Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol. 2003;43:309–34.CrossRefPubMed Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol. 2003;43:309–34.CrossRefPubMed
30.
go back to reference Chiang YR, Li A, Leu YL, et al. An in vitro study of the antimicrobial effects of indigo naturalis prepared from Strobilanthes formosanus Moore. Molecules. 2013;18:14381–96.CrossRefPubMed Chiang YR, Li A, Leu YL, et al. An in vitro study of the antimicrobial effects of indigo naturalis prepared from Strobilanthes formosanus Moore. Molecules. 2013;18:14381–96.CrossRefPubMed
31.
go back to reference Xiao HT, Peng J, Hu DD, et al. Qing-dai powder promotes recovery of colitis by inhibiting inflammatory responses of colonic macrophages in dextran sulfate sodium-treated mice. Chin Med. 2015;10:29.CrossRefPubMedPubMedCentral Xiao HT, Peng J, Hu DD, et al. Qing-dai powder promotes recovery of colitis by inhibiting inflammatory responses of colonic macrophages in dextran sulfate sodium-treated mice. Chin Med. 2015;10:29.CrossRefPubMedPubMedCentral
32.
go back to reference Li Y, Ligr M, McCarron JP, et al. Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion. Clin Cancer Res. 2011;17:4414–24.CrossRefPubMedPubMedCentral Li Y, Ligr M, McCarron JP, et al. Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion. Clin Cancer Res. 2011;17:4414–24.CrossRefPubMedPubMedCentral
33.
go back to reference Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495–549.CrossRefPubMed Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495–549.CrossRefPubMed
34.
go back to reference Takamura T, Harama D, Matsuoka S, et al. Activation of the aryl hydrocarbon receptor pathway may ameliorate dextran sodium sulfate-induced colitis in mice. Immunol Cell Biol. 2010;88:685–9.CrossRefPubMed Takamura T, Harama D, Matsuoka S, et al. Activation of the aryl hydrocarbon receptor pathway may ameliorate dextran sodium sulfate-induced colitis in mice. Immunol Cell Biol. 2010;88:685–9.CrossRefPubMed
35.
go back to reference Kociba RJ, Schwetz BA. Toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Drug Metab Rev. 1982;13:387–406. Kociba RJ, Schwetz BA. Toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Drug Metab Rev. 1982;13:387–406.
36.
go back to reference Pot C. Aryl hydrocarbon receptor controls regulatory CD4+ T cell function. Swiss Med Wkly. 2012;142:w13592.PubMed Pot C. Aryl hydrocarbon receptor controls regulatory CD4+ T cell function. Swiss Med Wkly. 2012;142:w13592.PubMed
37.
go back to reference Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:28–50.CrossRefPubMed Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:28–50.CrossRefPubMed
38.
go back to reference Groux H, O’Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737–42.CrossRefPubMed Groux H, O’Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737–42.CrossRefPubMed
39.
go back to reference Apetoh L, Quintana FJ, Pot C, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol. 2010;11:854–61.CrossRefPubMedPubMedCentral Apetoh L, Quintana FJ, Pot C, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol. 2010;11:854–61.CrossRefPubMedPubMedCentral
40.
go back to reference Mascanfroni ID, Takenaka MC, Yeste A, et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-alpha. Nat Med. 2015;21:638–46.CrossRefPubMedPubMedCentral Mascanfroni ID, Takenaka MC, Yeste A, et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-alpha. Nat Med. 2015;21:638–46.CrossRefPubMedPubMedCentral
41.
go back to reference Qiu J, Heller JJ, Guo X, et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity. 2012;36:92–104.CrossRefPubMed Qiu J, Heller JJ, Guo X, et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity. 2012;36:92–104.CrossRefPubMed
42.
go back to reference Wagage S, Harms Pritchard G, Dawson L, et al. The group 3 innate lymphoid cell defect in aryl hydrocarbon receptor deficient mice is associated with T cell hyperactivation during intestinal infection. PLoS One. 2015;10:e0128335.CrossRefPubMedPubMedCentral Wagage S, Harms Pritchard G, Dawson L, et al. The group 3 innate lymphoid cell defect in aryl hydrocarbon receptor deficient mice is associated with T cell hyperactivation during intestinal infection. PLoS One. 2015;10:e0128335.CrossRefPubMedPubMedCentral
43.
go back to reference Nikoopour E, Bellemore SM, Singh B. IL-22, cell regeneration and autoimmunity. Cytokine. 2015;74:35–42.CrossRefPubMed Nikoopour E, Bellemore SM, Singh B. IL-22, cell regeneration and autoimmunity. Cytokine. 2015;74:35–42.CrossRefPubMed
44.
go back to reference Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 2008;118:534–44.PubMedPubMedCentral Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 2008;118:534–44.PubMedPubMedCentral
45.
go back to reference Ji T, Xu C, Sun L, et al. Aryl hydrocarbon receptor activation down-regulates IL-7 and reduces inflammation in a mouse model of DSS-induced colitis. Dig Dis Sci. 2015;60:1958–66.CrossRefPubMed Ji T, Xu C, Sun L, et al. Aryl hydrocarbon receptor activation down-regulates IL-7 and reduces inflammation in a mouse model of DSS-induced colitis. Dig Dis Sci. 2015;60:1958–66.CrossRefPubMed
46.
go back to reference Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. J Gastroenterol. 2015;50:495–507.CrossRefPubMed Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. J Gastroenterol. 2015;50:495–507.CrossRefPubMed
47.
go back to reference Zhao Y, Ma T, Chen W, et al. MicroRNA-124 promotes intestinal inflammation by targeting aryl hydrocarbon receptor in Crohn’s disease. J Crohns Colitis. 2016;10:703–12.CrossRefPubMed Zhao Y, Ma T, Chen W, et al. MicroRNA-124 promotes intestinal inflammation by targeting aryl hydrocarbon receptor in Crohn’s disease. J Crohns Colitis. 2016;10:703–12.CrossRefPubMed
Metadata
Title
Indigo Naturalis ameliorates murine dextran sodium sulfate-induced colitis via aryl hydrocarbon receptor activation
Authors
Shoichiro Kawai
Hideki Iijima
Shinichiro Shinzaki
Satoshi Hiyama
Toshio Yamaguchi
Manabu Araki
Shuko Iwatani
Eri Shiraishi
Akira Mukai
Takahiro Inoue
Yoshito Hayashi
Masahiko Tsujii
Daisuke Motooka
Shota Nakamura
Tetsuya Iida
Tetsuo Takehara
Publication date
01-08-2017
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 8/2017
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-016-1292-z

Other articles of this Issue 8/2017

Journal of Gastroenterology 8/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.